According to literature reports, the median OS benefit from immunotherapy with PD-1 or PD-L1 inhibitors in patients with mucosal melanoma is significantly shorter compared to patients with cutaneous melanoma (18 months vs. 45 months, P=0.003), and significant efficacy is only observed in a subset of patients (24). This evidence concerns the gene CD274 and mucosal melanoma.